ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
-0,50%
Bitcoin
66.761,23
2,33%
Brent Oil
83,76
0,67%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) Notícias

MBRX

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBRX
DataHoraFonteTítuloCódigoCompanhia
16/05/202409:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
16/05/202409:32PR Newswire (US)Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressNASDAQ:MBRXMoleculin Biotech Inc
15/05/202409:38PR Newswire (US)Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)NASDAQ:MBRXMoleculin Biotech Inc
13/05/202411:53Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
13/05/202408:30PR Newswire (US)Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
10/05/202417:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
09/05/202409:30PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
08/05/202409:45PR Newswire (US)Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
07/05/202409:55PR Newswire (US)Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataNASDAQ:MBRXMoleculin Biotech Inc
02/05/202410:00PR Newswire (US)Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024NASDAQ:MBRXMoleculin Biotech Inc
01/05/202409:50PR Newswire (US)Moleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
18/04/202409:30PR Newswire (US)European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
10/04/202409:30PR Newswire (US)Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesNASDAQ:MBRXMoleculin Biotech Inc
28/03/202411:45PR Newswire (US)Moleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:MBRXMoleculin Biotech Inc
27/03/202410:25PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityNASDAQ:MBRXMoleculin Biotech Inc
27/03/202410:05PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLNASDAQ:MBRXMoleculin Biotech Inc
25/03/202408:30PR Newswire (US)Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialNASDAQ:MBRXMoleculin Biotech Inc
22/03/202417:05PR Newswire (US)Moleculin Reports Full Year 2023 Financial ResultsNASDAQ:MBRXMoleculin Biotech Inc
20/03/202408:30PR Newswire (US)Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
20/03/202408:15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:MBRXMoleculin Biotech Inc
19/03/202417:30PR Newswire (US)Moleculin Announces Reverse Stock SplitNASDAQ:MBRXMoleculin Biotech Inc
12/03/202410:05PR Newswire (US)Moleculin to Present at the 36th Annual ROTH ConferenceNASDAQ:MBRXMoleculin Biotech Inc
16/02/202419:19Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBRXMoleculin Biotech Inc
13/02/202402:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MBRXMoleculin Biotech Inc
02/02/202419:05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBRXMoleculin Biotech Inc
24/01/202410:50PR Newswire (US)Moleculin Announces 2023 Year-End Annamycin Clinical Trials Preliminary Data and 2024 Expectations for Multiple Data Readouts and Transition to Pivotal Phase 2B/3NASDAQ:MBRXMoleculin Biotech Inc
16/01/202419:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
05/01/202419:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:MBRXMoleculin Biotech Inc
27/12/202309:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MBRXMoleculin Biotech Inc
22/12/202319:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBRXMoleculin Biotech Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:MBRX

Seu Histórico Recente

BIT
NSCIT5719231
Romania
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados